PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 28, 2026Biomaterials Science0 citations

ROS-Responsive mPEG–PCL Nanoparticles for Co-Delivery of Paclitaxel Prodrug and R848 in Synergistic Chemo-Immunotherapy

QZQi ZhangLWLuyao WangZYZhaofan Yang

Key Points

  • The aim is to enhance antitumor efficacy through the co-delivery of a chemotherapy prodrug and an immune activator.
  • Development of ROS-responsive mPEG–PCL nanoparticles
  • Co-delivery of paclitaxel prodrug and R848
  • Assessment of pharmacokinetics and antitumor efficacy
  • Improved delivery and targeting of therapeutics
  • Enhanced immune activation observed
  • Demonstrated synergy between the chemotherapy and immunotherapy components

Abstract

Chemo-immunotherapy aims to integrate chemotherapy-induced antigen release with innate immune activation to achieve enhanced antitumor efficacy. However, the pharmacokinetic mismatch and systemic toxicity of free small molecules often compromise the...

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69c7722a8bbfbc51511e2604https://doi.org/10.1039/d5bm01811k
Ask AI
Helpful
Bookmark
Share
View Full Paper